EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches

Divya Chukkalore, Kira MacDougall, Viraj Master, Mehmet Asim Bilen, Bassel Nazha iD

The Oncologist · 06.09.2024 · 29 (9) · 738-746

DOI: 10.1093/oncolo/oyae029 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 21.02.2024. Verfasst von Divya Chukkalore und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Staten Island University Hospital, New York, NY, USA. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Immunotherapy, Molecular Targeted Therapy, Adrenal Cortex Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy in the advanced setting with poor prognosis. This narrative review provides an overview of the epidemiology of ACC and its molecular pathogenesis with a summary of the main involved signaling pathways. We then provide an update on the clinical presentation, diagnosis, and current management strategies of both localized and metastatic disease from a multidisciplinary perspective. We highlight the debate around the use of mitotane in the adjuvant setting and review the use of combination chemotherapy with etoposide, doxorubicin, and cisplatin. The review also focuses on emerging data providing hope for the use of immune checkpoint inhibitors and targeted therapies in ACC with a summary of ongoing trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenocortical CarcinomaImmunotherapyMolecular Targeted TherapyAdrenal Cortex NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

adrenal canceradrenocortical carcinomaimmunotherapytargeted therapytherapeutic options

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Staten Island University Hospital, New York, NY, USA.
  • Department of Hematology and Medical Oncology, the University of Oklahoma Medical Center, Oklahoma City, OK, USA.
  • Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.
  • Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.

ORCID-Profile: Bassel Nazha

Zitieren

APA

Chukkalore, D., MacDougall, K., Master, V., Bilen, M. A., & Nazha, B. (2024). Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches. The Oncologist, 29(9), 738-746. https://doi.org/10.1093/oncolo/oyae029

Vancouver

Chukkalore D, MacDougall K, Master V, Bilen MA, Nazha B. Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches. The Oncologist. 2024;29(9):738-746. doi:10.1093/oncolo/oyae029

BibTeX
@article{Chukkalore2024,
  author = {Chukkalore, Divya and MacDougall, Kira and Master, Viraj and Bilen, Mehmet Asim and Nazha, Bassel},
  title = {Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {9},
  pages = {738--746},
  doi = {10.1093/oncolo/oyae029}
}
Kostenlos starten →